Daewoong Pharmaceutical is accelerating its expansion in Latin America with the official launch of its botulinum toxin product, Nabota, in Ecuador.
Daewoong Pharmaceutical strengthens its Latin American footprint with the launch of its botulinum toxin, Nabota, in Ecuador, expanding its presence to 13 countries in the region.
Daewoong Pharmaceutical strengthens its Latin American footprint with the launch of its botulinum toxin, Nabota, in Ecuador, expanding its presence to 13 countries in the region.
The company said on Thursday that it hosted launch symposiums in two cities in Ecuador -- Guayaquil and Quito -- on Feb. 27 and 28, marking its entry into the Ecuadorian market. With this latest expansion, Nabota is now available in 13 out of 20 Latin American countries.
The launch symposium attracted approximately 240 cosmetic and plastic surgery specialists. The event featured key opinion leaders (KOLs) from Latin America, who conducted educational sessions on botulinum toxin treatments, skin boosters, and hyaluronic acid (HA) fillers.
“Nabota’s high purity of over 98 percent minimizes impurities and reduces resistance, making it highly effective for precise dosing and predictable therapeutic outcomes,” said Dr. Jacqueline Barreto Rodrigues, a Brazilian plastic surgeon and symposium speaker. “It is an optimal solution for addressing various patient needs, from frown lines to facial contouring.”
Since its initial entry into Panama in 2015, Daewoong’s Nabota has rapidly expanded across the region, penetrating key markets such as Brazil, Argentina, Chile, and Peru.
The product has achieved notable success in Latin America, recently securing an export contract worth 180 billion won ($124.4 million) with its Brazilian partner Moksha8, which is nearly ten times the size of its previous agreement.
Leveraging its proven quality and market success in the U.S., Europe, Brazil, and Thailand, Daewoong aims to position Nabota as a premium product in Ecuador by emphasizing its high safety profile. The company plans to strengthen its market presence by building a reliable distribution network and promoting best practices among healthcare professionals.
To support this initiative, Daewoong will offer training programs and reward systems for local medical professionals, ensuring long-term customer engagement and increasing trust in Nabota among Ecuadorian practitioners.
“Building on our success in Brazil and other Latin American markets, we are confident that Nabota will quickly gain traction in Ecuador,” Daewoong’s Nabota Business Division Head Yun Jun-su said. “We will continue expanding indications and exploring opportunities in the public procurement sector to achieve our goal of making Nabota a 1 trillion won brand.”
tweet
Related articles
Daewoong secures landmark BTX export deal in Latin America
Daewoong Pharm marks record-breaking performance driven by new drugs and global expansion plan
Daewoong expands BTX business in ME market with Saudi Arabian launch
Daewoong, ST Pharm, Huons among winners of 2024 World-Class Product of Korea certification
Lee Han-soo corea022@docdocdoc.co.kr
See Other Articles
Copyright © KBR Unauthorized reproduction, redistribution prohibited